NEW YORK — A federal securities class action lawsuit has been filed against Boston Scientific Corporation, and investors who purchased shares during a specified period have until May 4, 2026, to seek appointment as lead plaintiff, according to a notice from securities law firm Faruqi & Faruqi, LLP.
The case centers on allegations that the company and its executives misled investors about the strength and sustainability of its U.S. electrophysiology (EP) business. The complaint claims Boston Scientific overstated the segment’s growth prospects while failing to disclose that the business was nearing a slowdown sooner than expected.
According to the filing, company statements projecting continued growth left investors unprepared for weaker-than-expected financial results and guidance issued earlier this year.
On February 4, 2026, Boston Scientific released its fourth-quarter and full-year 2025 results, reporting disappointing U.S. EP sales and issuing fiscal 2026 guidance that fell short of market expectations. The company cited slower market growth and rising competition, despite earlier assurances that management had a strong understanding of competitive pressures and timing.
Following the announcement, Boston Scientific’s stock dropped $16.12, or 17.6 percent, closing at $75.50 per share, according to the complaint.
The lawsuit seeks to represent investors who purchased or acquired Boston Scientific securities between July 23, 2025, and February 3, 2026. The court-appointed lead plaintiff will be the investor with the largest financial stake in the case who can adequately represent the class and oversee the litigation.
Faruqi & Faruqi said investors who suffered losses during the period may contact the firm to discuss their legal options. The firm also encouraged individuals with relevant information, including former employees or whistleblowers, to come forward.
